Endocrine resistance affects over 30% of patients with estrogen receptor positive (ER+) breast cancer, and a deeper understanding of the mechanisms driving resistance is sorely needed for improving patient outcomes.
Advances in chromatin conformation capture technologies like Hi-C have helped us uncover mechanisms through which complex disorders and diseases, including cancer, emerge. As our understanding of 3D genome architecture grows, so does our ability to therapeutically target disease. During this webinar, you will:
- Learn about promoter capture Hi-C as a technique used to study the 3D genome.
- See how promoter capture Hi-C was used to identify epigenetic events leading to tumor growth in endocrine-resistant breast cancer models.
- Discover how epigenetic therapy with Decitabine, a DNA methylation inhibitor, suppresses tumor growth in ER+ endocrine-resistant breast cancer models through a rewiring of the 3D genome.
About the speaker
Dr. Joanna Achinger-KaweckaPostdoctoral Fellow at the Garvan Institute
Dr. Joanna Achinger-Kawecka received her PhD from the University of Tuebingen, Germany, where she investigated microRNA signatures as predictive biomarkers for breast cancer. Following her PhD, she joined the laboratory of Professor Susan Clark at the Garvan Institute in Sydney, Australia, where she established cutting-edge experimental and computational approaches to study the 3D genome organization in cancer. Dr. Achinger-Kawecka's research is focused on investigating the role of the 3D epigenome in cancer, particularly in driving tumor progression and treatment resistance.